• 1
    Diehr P, Patrick DL, McDonell MB, Fihn SD. Accounting for deaths in longitudinal studies using the SF-36: The performance of the physical component scale of the Short Form 36-Item Health Survey and the PCTD. Med Care 2003;41:106573.
  • 2
    Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000;9:887900.
  • 3
    Rothman ML, Beltran P, Cappelleri JC, et al. Patient-reported outcomes: conceptual issues. Value Health 2007;10(Suppl. 2):S6675.
  • 4
    Snyder CF, Watson ME, Jackson JD, et al. Patient-Reported Outcome Instrument Selection: designing a measurement strategy. Value Health 2007;10(Suppl. 2):S7685.
  • 5
    Turner RR, Quittner AL, Parasuraman BM, et al. Patient-Reported Outcomes: instrument development and selection issues. Value Health 2007;10(Suppl. 2):S8693.
  • 6
    Frost MH, Reeve BB, Liepa AM, et al. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 2007;10(Suppl. 2):S94105.
  • 7
    Sloan JA, Dueck AC, Erickson PA, et al. Analysis and interpretation of results based on patient-reported outcomes. Value Health 2007;10(Suppl. 2):S10615.
  • 8
    Osoba D, Bezjak A, Brundage M, Pater J. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health 2007;10(Suppl. 2):S13845.
  • 9
    Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007;10(Suppl. 2):S12537.
  • 10
    Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med 1998;17:78196.
  • 11
    Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. New York: Chapman & Hall/CRC, 2002.
  • 12
    Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:7396.
  • 13
    Donaldson GW, Moinpour CM. Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 2005;23:73804.
  • 14
    Huntington JL, Dueck A. Handling missing data. Curr Probl Cancer 2005;29:31725.
  • 15
    Fairclough DL, Cella DF. Functional assessment of cancer therapy (FACT-G): Non-response to individual questions. Qual Life Res 1996;5:3219.
  • 16
    Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. New York: John Wiley & Sons, 2004.
  • 17
    Hedecker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Meth 1997;2:6478.
  • 18
    Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York: Oxford University Press, 2003.
  • 19
    Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester: John Wiley & Sons, 1999.
  • 20
    Pauler DK, McCoy S, Moinpour C. Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Stat Med 2003;22:795809.
  • 21
    Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997;16:1197209.
  • 22
    Troxel AB, Fairclough DL, Curran D, Hahn EA. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med 1998;17:65366.
  • 23
    Fayers P, Machin D. Quality of Life Assessment, Analysis and Interpretation. New York: John Wiley, 2000.
  • 24
    Thijs H, Molenberghs G, Jansen I. Missing data: sensitivity analyses. In: Lenderking, WR, Revicki, DA, eds. Advancing Health Outcomes Research Methods and Clinical Applications. Mclean, VA: International Society for Quality of Life Research, 2005.
  • 25
    Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag, 2000.
  • 26
    Fayers P, Hays R. Assessing Quality of Life in Clinical Trials: Methods and Practice. New York: Oxford University Press, 2005.
  • 27
    Fairclough DL. Analysis and Interpretation of Results Based on Patient-Reported Outcomes. Value Health 2007;10(Suppl. 2):S10615.
  • 28
    Revicki DA. Preventing missing data. In: FayersP, HaysRD, eds. Assessing Quality of Life in Clinical Trials, 2nd edn. New York: Oxford University Press, 2005.
  • 29
    Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:134153.
  • 30
    Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:260617.
  • 31
    Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:72940.
  • 32
    Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: Preliminary definition of improvement in rheumatoid arthritis. [see comment]. Arthritis Rheum 1995;38:72735.
  • 33
    Sloan JA. Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. COPD. J Chron Obstr Pulm Dis 2005;2:5762.
  • 34
    Revicki DA, Gold K, Buckman D, et al. Imputing physical health status scores missing owing to mortality: Results of a simulation comparing multiple techniques. Med Care 2001;39:6171.
  • 35
    Diehr P, Patrick DL, Spertus J, et al. Transforming self-rated health and the SF-36 scales to include death and improve interpretability. Med Care 2001;39:67080.
  • 36
    Enders CK. A primer on the use of modern missing-data methods in psychosomatic medicine research. Psychosom Med 2006;68:42736.
  • 37
    Fayers P, Machin D, Fayers PM. Practical and reporting issues. In: FayersP, MachinD, eds., Quality of Life Assessment. Analysis, and Interpretation. Chichester: John Wiley & Sons, 2000.
  • 38
    Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:6570.
  • 39
    Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:8002.
  • 40
    Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:7396.
  • 41
    Mandrekar S, Kamath C. Presenting longitudinal data. Applying QOL assessments: solution for oncology clinical practice research, part 1. Curr Prob Cancer 2005;29:296305.
  • 42
    Stevens J. Applied Multivariate Statistics for the Social Sciences (3rd ed.). Mahwah, NJ: Lawrence Erlbaum Associates, 1996.
  • 43
    Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006;24:63542.
  • 44
    Fairclough D. Analysing studies with missing data. In: Fayers, P, Hays, RD, eds. Assessing Quality of Life in Clinical Trials, 2nd edn. New York: Oxford University Press, 2005.